Target Price | $125.58 |
Price | $93.87 |
Potential |
33.78%
register free of charge
|
Number of Estimates | 19 |
19 Analysts have issued a price target Blueprint Medicines Corp. 2025 .
The average Blueprint Medicines Corp. target price is $125.58.
This is
33.78%
register free of charge
$167.00
77.91%
register free of charge
$81.00
13.71%
register free of charge
|
|
A rating was issued by 20 analysts: 14 Analysts recommend Blueprint Medicines Corp. to buy, 5 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Blueprint Medicines Corp. stock has an average upside potential 2025 of
33.78%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 249.38 | 508.95 |
22.22% | 104.09% | |
EBITDA Margin | -190.32% | -36.22% |
24.95% | 80.97% | |
Net Margin | -212.96% | -12.19% |
26.76% | 94.28% |
19 Analysts have issued a sales forecast Blueprint Medicines Corp. 2024 . The average Blueprint Medicines Corp. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Blueprint Medicines Corp. EBITDA forecast 2024. The average Blueprint Medicines Corp. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Blueprint Medicines Corp. Analysts have issued a net profit forecast 2024. The average Blueprint Medicines Corp. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -8.37 | -0.98 |
10.48% | 88.29% | |
P/E | negative | |
EV/Sales | 11.71 |
18 Analysts have issued a Blueprint Medicines Corp. forecast for earnings per share. The average Blueprint Medicines Corp. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Blueprint Medicines Corp. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Blueprint Medicines Corp....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.